Revisiting mTOR inhibitors as anticancer agents

Qiu Xu Teng, Yunali V. Ashar, Pranav Gupta, Eddie Gadee, Ying Fang Fan, Sandra E. Reznik, John N.D. Wurpel, Zhe Sheng Chen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates a variety of cellular processes, influencing diverse pathological conditions including a variety of cancers. Accordingly, therapies that target mTOR as anticancer agents benefit patients in various clinical settings. It is therefore important to fully investigate mTOR signaling at a molecular level and corresponding mTOR inhibitors to identify additional clinical opportunities of targeting mTOR in cancers. In this review, we introduce the function and regulation of the mTOR signaling pathway and organize and summarize the different roles of mTOR in cancers and a variety of mTOR inhibitors that can be used as anticancer agents. This article aims to enlighten and guide the development of mTOR-targeted anticancer agents in the future.

Original languageEnglish (US)
Pages (from-to)2086-2095
Number of pages10
JournalDrug Discovery Today
Volume24
Issue number10
DOIs
StatePublished - Oct 2019

Fingerprint

Sirolimus
Antineoplastic Agents
Neoplasms
Protein-Serine-Threonine Kinases

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Teng, Q. X., Ashar, Y. V., Gupta, P., Gadee, E., Fan, Y. F., Reznik, S. E., ... Chen, Z. S. (2019). Revisiting mTOR inhibitors as anticancer agents. Drug Discovery Today, 24(10), 2086-2095. https://doi.org/10.1016/j.drudis.2019.05.030

Revisiting mTOR inhibitors as anticancer agents. / Teng, Qiu Xu; Ashar, Yunali V.; Gupta, Pranav; Gadee, Eddie; Fan, Ying Fang; Reznik, Sandra E.; Wurpel, John N.D.; Chen, Zhe Sheng.

In: Drug Discovery Today, Vol. 24, No. 10, 10.2019, p. 2086-2095.

Research output: Contribution to journalReview article

Teng, QX, Ashar, YV, Gupta, P, Gadee, E, Fan, YF, Reznik, SE, Wurpel, JND & Chen, ZS 2019, 'Revisiting mTOR inhibitors as anticancer agents', Drug Discovery Today, vol. 24, no. 10, pp. 2086-2095. https://doi.org/10.1016/j.drudis.2019.05.030
Teng QX, Ashar YV, Gupta P, Gadee E, Fan YF, Reznik SE et al. Revisiting mTOR inhibitors as anticancer agents. Drug Discovery Today. 2019 Oct;24(10):2086-2095. https://doi.org/10.1016/j.drudis.2019.05.030
Teng, Qiu Xu ; Ashar, Yunali V. ; Gupta, Pranav ; Gadee, Eddie ; Fan, Ying Fang ; Reznik, Sandra E. ; Wurpel, John N.D. ; Chen, Zhe Sheng. / Revisiting mTOR inhibitors as anticancer agents. In: Drug Discovery Today. 2019 ; Vol. 24, No. 10. pp. 2086-2095.
@article{5ba1dde8b0dc4daa91ac7eafbe5d1201,
title = "Revisiting mTOR inhibitors as anticancer agents",
abstract = "The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates a variety of cellular processes, influencing diverse pathological conditions including a variety of cancers. Accordingly, therapies that target mTOR as anticancer agents benefit patients in various clinical settings. It is therefore important to fully investigate mTOR signaling at a molecular level and corresponding mTOR inhibitors to identify additional clinical opportunities of targeting mTOR in cancers. In this review, we introduce the function and regulation of the mTOR signaling pathway and organize and summarize the different roles of mTOR in cancers and a variety of mTOR inhibitors that can be used as anticancer agents. This article aims to enlighten and guide the development of mTOR-targeted anticancer agents in the future.",
author = "Teng, {Qiu Xu} and Ashar, {Yunali V.} and Pranav Gupta and Eddie Gadee and Fan, {Ying Fang} and Reznik, {Sandra E.} and Wurpel, {John N.D.} and Chen, {Zhe Sheng}",
year = "2019",
month = "10",
doi = "10.1016/j.drudis.2019.05.030",
language = "English (US)",
volume = "24",
pages = "2086--2095",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Revisiting mTOR inhibitors as anticancer agents

AU - Teng, Qiu Xu

AU - Ashar, Yunali V.

AU - Gupta, Pranav

AU - Gadee, Eddie

AU - Fan, Ying Fang

AU - Reznik, Sandra E.

AU - Wurpel, John N.D.

AU - Chen, Zhe Sheng

PY - 2019/10

Y1 - 2019/10

N2 - The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates a variety of cellular processes, influencing diverse pathological conditions including a variety of cancers. Accordingly, therapies that target mTOR as anticancer agents benefit patients in various clinical settings. It is therefore important to fully investigate mTOR signaling at a molecular level and corresponding mTOR inhibitors to identify additional clinical opportunities of targeting mTOR in cancers. In this review, we introduce the function and regulation of the mTOR signaling pathway and organize and summarize the different roles of mTOR in cancers and a variety of mTOR inhibitors that can be used as anticancer agents. This article aims to enlighten and guide the development of mTOR-targeted anticancer agents in the future.

AB - The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates a variety of cellular processes, influencing diverse pathological conditions including a variety of cancers. Accordingly, therapies that target mTOR as anticancer agents benefit patients in various clinical settings. It is therefore important to fully investigate mTOR signaling at a molecular level and corresponding mTOR inhibitors to identify additional clinical opportunities of targeting mTOR in cancers. In this review, we introduce the function and regulation of the mTOR signaling pathway and organize and summarize the different roles of mTOR in cancers and a variety of mTOR inhibitors that can be used as anticancer agents. This article aims to enlighten and guide the development of mTOR-targeted anticancer agents in the future.

UR - http://www.scopus.com/inward/record.url?scp=85067171782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067171782&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.05.030

DO - 10.1016/j.drudis.2019.05.030

M3 - Review article

C2 - 31173912

AN - SCOPUS:85067171782

VL - 24

SP - 2086

EP - 2095

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 10

ER -